Pfizer gets USFDA approval for Vyndaqel, Vyndamax to treat amyloidosis cardiomyopathy Farhat Nasim11 May 2019 9:15 AM ISTNew Delhi: Pfizer Inc's subsidiary FoldRx, has recently won U.S. Food and Drug Administration (USFDA) approved for Vyndaqel (tafamidis meglumine) and...
Pfizer gets USFDA nod for potential blockbuster heart drug Tafamidis Medical Dialogues Bureau7 May 2019 9:45 AM ISTPfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under...